These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 18095129)

  • 21. Prolactin receptor expression in gynaecomastia and male breast carcinoma.
    Ferreira M; Mesquita M; Quaresma M; André S
    Histopathology; 2008 Jul; 53(1):56-61. PubMed ID: 18613925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymphocytic prolactin does not contribute to systemic lupus erythematosus hyperprolactinemia.
    Paraiba DB; Soares CR; Bartolini P; Arthuso FS; Borba EF; Bonfa E; Bronstein MD
    Clin Exp Rheumatol; 2010; 28(6):866-72. PubMed ID: 21205462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic value of thyrotropin releasing hormone test in 129 patients with suspected tumoral hyperprolactinemia.
    Smircić-Duvnjak L; Vizner B; Korsić M; Sekso M; Berković M
    Coll Antropol; 2002 Dec; 26(2):635-40. PubMed ID: 12528293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melatonin circadian rhythm in women with idiopathic hyperprolactinemia.
    Karasek M; Stawerska R; Hilczer M; Zylinska K; Lewinski A
    Neuro Endocrinol Lett; 2004 Dec; 25(6):411-4. PubMed ID: 15665801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between prolactin (PRL), leptin, nitric oxide (NO), and cytokines in patients with hyperprolactinemia.
    Balci H; Akgun-Dar K; Gazioglu N; Kapucu A; Bolayirli M; Oz B
    Pituitary; 2009; 12(3):170-6. PubMed ID: 18752070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperprolactinemia in multiple endocrine adenomatosis, type 1.
    Carlson HE; Levine GA; Goldberg NJ; Hershman JM
    Arch Intern Med; 1978 Dec; 138(12):1807-8. PubMed ID: 31144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolactin decreases expression of Runx2, osteoprotegerin, and RANKL in primary osteoblasts derived from tibiae of adult female rats.
    Charoenphandhu N; Teerapornpuntakit J; Methawasin M; Wongdee K; Thongchote K; Krishnamra N
    Can J Physiol Pharmacol; 2008 May; 86(5):240-8. PubMed ID: 18432284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and cellular localization of prolactin and the prolactin receptor in mammalian retina.
    Rivera JC; Aranda J; Riesgo J; Nava G; Thebault S; López-Barrera F; Ramírez M; Martínez de la Escalera G; Clapp C
    Exp Eye Res; 2008 Feb; 86(2):314-21. PubMed ID: 18096157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macroprolactin: what is it and what is its importance?
    Sadideen H; Swaminathan R
    Int J Clin Pract; 2006 Apr; 60(4):457-61. PubMed ID: 16620360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reproductive role of prolactin.
    Bachelot A; Binart N
    Reproduction; 2007 Feb; 133(2):361-9. PubMed ID: 17307904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunohistochemistry for pituitary hormones and Ki-67 in growth hormone producing pituitary adenomas].
    Brito J; Sáez L; Lemp M; Liberman C; Michelsen H; Araya AV
    Rev Med Chil; 2008 Jul; 136(7):831-6. PubMed ID: 18949157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The importance of hyperprolactinemia in impotence.
    Netto Júnior NR; Claro Jde A
    Rev Paul Med; 1993; 111(6):454-5. PubMed ID: 8052792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolactin receptor expression in lymphocytes from patients with hyperprolactinemia or acromegaly.
    Leite-de-Moraes MC; Touraine P; Kelly PA; Kuttenn F; Dardenne M
    J Endocrinol; 1995 Nov; 147(2):353-9. PubMed ID: 7490565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Macroprolactin, big-prolactin and potential effects on the misdiagnosis of hyperprolactinemia using the Beckman Coulter Access Prolactin assay.
    Ellis MJ; Livesey JH; Soule SG
    Clin Biochem; 2006 Oct; 39(10):1028-34. PubMed ID: 16919253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of cyclase activating (CAP) and cyclase inhibiting (CIP) parathormone fractions in the assessment of bone metabolism disturbances in women with hyperprolactinemia of various origin.
    Zadrozna-Sliwka B; Bolanowski M; Jawiarczyk A; Kaluzny M; Syrycka J
    Neuro Endocrinol Lett; 2008 Feb; 29(1):178-84. PubMed ID: 18283239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An evaluation of patients with hyperprolactinemia: have dynamic tests had their day?
    Di Sarno A; Rota F; Auriemma R; De Martino MC; Lombardi G; Colao A
    J Endocrinol Invest; 2003; 26(7 Suppl):39-47. PubMed ID: 14604065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study.
    Wallaschofski H; Eigenthaler M; Kiefer M; Donné M; Hentschel B; Gertz HJ; Lohmann T
    J Clin Psychopharmacol; 2003 Oct; 23(5):479-83. PubMed ID: 14520125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome.
    Tsamandas AC; Kardamakis D; Tsiamalos P; Liava A; Tzelepi V; Vassiliou V; Petsas T; Vagenas K; Zolota V; Scopa CD
    Anticancer Res; 2009 Feb; 29(2):703-9. PubMed ID: 19331225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of association between hyperprolactinemia and colon carcinoma.
    Carlson HE; Zarrabi MH; Lyubsky SL
    Cancer Invest; 2000; 18(2):130-4. PubMed ID: 10705875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pattern of development of hyperprolactinemia after initiation of haloperidol therapy.
    Spitzer M; Sajjad R; Benjamin F
    Obstet Gynecol; 1998 May; 91(5 Pt 1):693-5. PubMed ID: 9572212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.